SCHEMBL6280461

SCHEMBL6280461

C[C@H](O)Cn1ncc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.53
KMO O15229 2/20 0.51
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.49
HTR2A P28223 4/20 0.48
HTR2C P28335 4/20 0.48
HTR1A P08908 2/20 0.48
ADRA2A P08913 2/20 0.48
ADRA2B P18089 2/20 0.48
ADRA2C P18825 2/20 0.48
HTR2B P41595 2/20 0.48
HTR1D P28221 1/20 0.48
HTR7 P34969 1/20 0.48
HTR4 Q13639 1/20 0.48
CHRM2 P08172 9/20 0.46
CHRM1 P11229 9/20 0.46
CHRM3 P20309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30259947 0.86 RECQL (0.56) RECQLKMONPC1RAB9AMEN1
SCHEMBL8888398 0.86 RECQL (0.56) RECQLKMONPC1RAB9AMEN1
SCHEMBL17504334 0.83 CHRM2 (0.50) RECQLKMONPC1RAB9AMEN1
SCHEMBL16122395 0.83 CHRM2 (0.50) RECQLKMONPC1RAB9AMEN1
SCHEMBL17504336 0.83 CHRM2 (0.50) RECQLKMONPC1RAB9AMEN1
SCHEMBL17504270 0.81 RECQL (0.56) RECQLKMONPC1RAB9AMEN1
SCHEMBL7141152 0.81 RECQL (0.51) RECQLKMONPC1RAB9AMEN1
SCHEMBL16122654 0.81 RECQL (0.56) RECQLKMONPC1RAB9AMEN1
SCHEMBL17504280 0.80 CHRM2 (0.50) RECQLKMONPC1RAB9AMEN1
SCHEMBL16122396 0.80 CHRM2 (0.50) RECQLKMONPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875765-B2 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2005-04-05 US disclosed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof CASP1, IRAK1, STS RECQL 2311/4885KMO 855/4885NPC1 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.